Cargando…
The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-relat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843192/ https://www.ncbi.nlm.nih.gov/pubmed/35132912 http://dx.doi.org/10.1080/07853890.2022.2034931 |
_version_ | 1784651202321973248 |
---|---|
author | Zhu, Wen Li, Yehui Zhao, Junjie Wang, Yifan Li, Yixi Wang, Yue |
author_facet | Zhu, Wen Li, Yehui Zhao, Junjie Wang, Yifan Li, Yixi Wang, Yue |
author_sort | Zhu, Wen |
collection | PubMed |
description | BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-related interstitial lung disease (CTD-ILD) for many years. Triptolide is a key effective component from Tripterygium wilfordii. But the molecular mechanism of Triptolide for treating CTD-ILD is not yet clear. METHODS: Gaining insight into the molecular mechanism of Triptolide intervention CTD-ILD, we used the method of network pharmacology. And then we conducted drug-target networks to analyse the potential protein targets between Triptolide and CTD-ILD. Finally, AutoDock Vina was selected for molecular docking. RESULTS: By analysing the interaction genes between Triptolide and CTD-ILD, 242 genes were obtained. The top 10 targets of the highest enrichment scores were STAT3, AKT1, MAPK1, IL6, TP53, MAPK3, RELA, TNF, JUN, JAK2. GO and KEGG enrichment analysis exhibited that multiple signalling pathways were involved. PI3K-Akt, multiple virus infections, cancer signalling, chemokine, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. And it is related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. Molecular docking shows Triptolide can bind with its target protein in a good bond by intermolecular force. CONCLUSIONS: This study preliminarily reveals the internal molecular mechanism of Triptolide interfere with CTD-ILD through multiple targets, multiple access, validated through molecular docking. KEY MESSAGES: Triptolide intervention CTD-ILD, which are related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. PI3K-Akt, multiple virus infections, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. Triptolide can bind with related target protein in a good bond by Intermolecular force, exhibiting a good docking activity. |
format | Online Article Text |
id | pubmed-8843192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-88431922022-02-15 The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking Zhu, Wen Li, Yehui Zhao, Junjie Wang, Yifan Li, Yixi Wang, Yue Ann Med Pulmonary Medicine BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-related interstitial lung disease (CTD-ILD) for many years. Triptolide is a key effective component from Tripterygium wilfordii. But the molecular mechanism of Triptolide for treating CTD-ILD is not yet clear. METHODS: Gaining insight into the molecular mechanism of Triptolide intervention CTD-ILD, we used the method of network pharmacology. And then we conducted drug-target networks to analyse the potential protein targets between Triptolide and CTD-ILD. Finally, AutoDock Vina was selected for molecular docking. RESULTS: By analysing the interaction genes between Triptolide and CTD-ILD, 242 genes were obtained. The top 10 targets of the highest enrichment scores were STAT3, AKT1, MAPK1, IL6, TP53, MAPK3, RELA, TNF, JUN, JAK2. GO and KEGG enrichment analysis exhibited that multiple signalling pathways were involved. PI3K-Akt, multiple virus infections, cancer signalling, chemokine, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. And it is related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. Molecular docking shows Triptolide can bind with its target protein in a good bond by intermolecular force. CONCLUSIONS: This study preliminarily reveals the internal molecular mechanism of Triptolide interfere with CTD-ILD through multiple targets, multiple access, validated through molecular docking. KEY MESSAGES: Triptolide intervention CTD-ILD, which are related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. PI3K-Akt, multiple virus infections, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. Triptolide can bind with related target protein in a good bond by Intermolecular force, exhibiting a good docking activity. Taylor & Francis 2022-02-08 /pmc/articles/PMC8843192/ /pubmed/35132912 http://dx.doi.org/10.1080/07853890.2022.2034931 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pulmonary Medicine Zhu, Wen Li, Yehui Zhao, Junjie Wang, Yifan Li, Yixi Wang, Yue The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title | The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title_full | The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title_fullStr | The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title_full_unstemmed | The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title_short | The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
title_sort | mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking |
topic | Pulmonary Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843192/ https://www.ncbi.nlm.nih.gov/pubmed/35132912 http://dx.doi.org/10.1080/07853890.2022.2034931 |
work_keys_str_mv | AT zhuwen themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT liyehui themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT zhaojunjie themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT wangyifan themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT liyixi themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT wangyue themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT zhuwen mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT liyehui mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT zhaojunjie mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT wangyifan mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT liyixi mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking AT wangyue mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking |